Free Trial

Coloplast A/S (CLPBY) Stock Forecast & Price Target

Coloplast A/S logo
$9.92 +0.25 (+2.59%)
As of 09/5/2025 03:56 PM Eastern

Coloplast A/S - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Sell
0
Hold
4
Buy
1

Based on 5 Wall Street analysts who have issued ratings for Coloplast A/S in the last 12 months, the stock has a consensus rating of "Hold." Out of the 5 analysts, 4 have given a hold rating, and 1 has given a strong buy rating for CLPBY.

Consensus Price Target

N/A

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for CLPBY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Coloplast A/S and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CLPBY Analyst Ratings Over Time

TypeCurrent Forecast
9/6/24 to 9/6/25
1 Month Ago
8/7/24 to 8/7/25
3 Months Ago
6/8/24 to 6/8/25
1 Year Ago
9/7/23 to 9/6/24
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
0 Buy rating(s)
0 Buy rating(s)
0 Buy rating(s)
0 Buy rating(s)
Hold
4 Hold rating(s)
4 Hold rating(s)
4 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price TargetN/AN/AN/AN/A
Forecasted UpsideN/AN/AN/AN/A
Consensus RatingHoldHoldHoldHold

CLPBY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CLPBY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Coloplast A/S Stock vs. The Competition

TypeColoplast A/SMedical CompaniesS&P 500
Consensus Rating Score
2.40
2.78
2.53
Consensus RatingHoldModerate BuyModerate Buy
Predicted UpsideN/A16,022.82% Upside10.36% Upside
News Sentiment Rating
Positive News

See Recent CLPBY News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
5/9/2025Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
J. Reynolds-Clar
Not Rated
DowngradeModerate BuyHold
5/7/2025Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
H. Al-Wakeel
Not Rated
DowngradeStrong-BuyHold
1/28/2025Sanford C. Bernstein
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
L. Clive
Not Rated
UpgradeHoldStrong-Buy
12/11/2024UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong SellHold
11/18/2024Hsbc Global Res
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeModerate SellHold

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 06:16 AM ET.


Should I Buy Coloplast A/S Stock? CLPBY Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, September 2, 2025. Please send any questions or comments about these Coloplast A/S pros and cons to contact@marketbeat.com.

Coloplast A/S
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Coloplast A/S:

  • Coloplast A/S has recently experienced a significant decline in short interest, indicating increased investor confidence. A drop of 42.2% in short interest suggests that fewer investors are betting against the stock, which can be a positive sign for potential growth.
  • The company operates in the intimate healthcare sector, which is expected to grow due to increasing awareness and demand for healthcare products, particularly in chronic and continence care.
  • Coloplast A/S offers a diverse range of innovative products, including the latest versions of ostomy care solutions like SenSura Mio, which are designed for optimal discretion and fit, appealing to a broad customer base.
  • The current stock price is around $XX, reflecting a stable position in the market, which can attract long-term investors looking for reliable growth opportunities.
  • With a strong presence in multiple international markets, including the United States and Europe, Coloplast A/S is well-positioned to capitalize on global healthcare trends and expand its market share.

Coloplast A/S
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Coloplast A/S for these reasons:

  • Despite the recent decline in short interest, the overall market volatility can still pose risks, as fluctuations may impact stock performance and investor sentiment.
  • The healthcare sector is highly competitive, and Coloplast A/S faces challenges from other companies offering similar products, which could affect its market position and profitability.
  • Regulatory changes in healthcare policies across different countries can impact the company's operations and profitability, introducing uncertainty for investors.
  • While the company has a strong product lineup, any delays in product development or market introduction could hinder growth prospects and investor confidence.
  • Investors should consider the potential for economic downturns, which can lead to reduced healthcare spending and negatively affect sales for Coloplast A/S.

CLPBY Forecast - Frequently Asked Questions

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Coloplast A/S in the last year. There are currently 4 hold ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" CLPBY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CLPBY, but not buy additional shares or sell existing shares.

According to analysts, Coloplast A/S's stock has a predicted downside of -100.00% based on their 12-month stock forecasts.

Analysts like Coloplast A/S less than other "medical" companies. The consensus rating for Coloplast A/S is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how CLPBY compares to other companies.


This page (OTCMKTS:CLPBY) was last updated on 9/6/2025 by MarketBeat.com Staff
From Our Partners